Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. 1986

J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman

Formation of syncytia, with progression to cell death, is a characteristic feature of in vitro cultures of susceptible cells infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). Viral antigen-positive multinucleated giant cells have also been observed in histological sections from infected individuals. In vitro, formation of these multinucleated giant cells occurs through cell fusion which is dependent on cell-surface expression of the differentiation antigen CD4. Utilizing a recombinant vaccinia virus containing the gene for the envelope glycoprotein of HTLV-III/LAV, we demonstrate that cell-surface expression of this protein, in the absence of other HTLV-III/LAV structural or regulatory proteins, is sufficient to induce CD4-dependent cell fusion, leading to cell death, one of the characteristic manifestations of AIDS (acquired immune deficiency syndrome) virus cytopathology. This process may contribute to the loss of CD4+ T cells seen in AIDS.

UI MeSH Term Description Entries
D002459 Cell Fusion Fusion of somatic cells in vitro or in vivo, which results in somatic cell hybridization. Cell Fusions,Fusion, Cell,Fusions, Cell
D002472 Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus. Transformation, Viral Cell,Viral Cell Transformation,Cell Transformations, Viral,Transformations, Viral Cell,Viral Cell Transformations
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005452 Fluoresceins A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays. Tetraiodofluorescein
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013861 Thiocyanates Organic derivatives of thiocyanic acid which contain the general formula R-SCN. Rhodanate,Rhodanates
D014616 Vaccinia virus The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS. Buffalopox virus,Poxvirus officinale,Rabbitpox virus,Buffalo Pox Virus,Rabbit Pox Virus,Buffalo Pox Viruses,Buffalopox viruses,Rabbit Pox Viruses,Rabbitpox viruses,Vaccinia viruses,Virus, Buffalo Pox,Viruses, Buffalo Pox,virus, Buffalopox

Related Publications

J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
January 1986, Nature,
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
January 1987, Haematology and blood transfusion,
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
January 1986, Nature,
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
September 1985, Science (New York, N.Y.),
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
February 1987, Journal of immunology (Baltimore, Md. : 1950),
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
January 1986, Nordisk medicin,
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
March 1986, Deutsche medizinische Wochenschrift (1946),
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
May 1986, Deutsche medizinische Wochenschrift (1946),
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
November 1985, Biochemical pharmacology,
J D Lifson, and M B Feinberg, and G R Reyes, and L Rabin, and B Banapour, and S Chakrabarti, and B Moss, and F Wong-Staal, and K S Steimer, and E G Engleman
November 1985, Lancet (London, England),
Copied contents to your clipboard!